Lonial emphasizes that the EXCALIBER-RRMM trial is a test case for a new regulatory framework. The study utilizes dual primary end points to satisfy both accelerated and full approval requirements: ...

Reducing Uncertainty in the Care and Treatment of Blood Cancer ST. LOUIS, MO, UNITED STATES, February 23, 2026 ...

For patients facing a multiple myeloma diagnosis, the journey is often defined by a search for the next line of defense. For survivor Julie Cohen, that search led her to the front lines of medical ...

Experts weigh perioperative immunotherapy delays, rapid molecular testing, ctDNA MRD and emerging ADCs shaping early-stage lung cancer care. In this summary of a panel discussion at the 2026 TTLC ...

C4 Therapeutics (NASDAQ:CCCC) used a presentation at TD Cowen’s 46th Annual Healthcare Conference to outline its near- and mid-term clinical plans, emphasizing its lead multiple myeloma program ...

The FDA has issued a draft guidance for industry on use of minimal residual disease (MRD) and complete response rates as primary trial endpoints for accelerated approval of multiple myeloma drugs. In ...

Six presented abstracts at ASCO-GU 2026 reinforce the clinical impact of Myriad’s Precise MRD, Prolaris, and MyRisk tests ...

Multiple insider sales by senior executives at Adaptive Biotechnologies (NasdaqGS:ADPT) were disclosed following the company’s strong quarterly results. The CEO and Chief Scientific Officer reported ...

Liquid biopsy encompasses a variety of molecular approaches to detect circulating tumor DNA (ctDNA) and has become a powerful tool in the diagnosis and treatment of solid tumors. Current applications ...

Total revenue of $68.7 million in 4Q25 and $172.4 million in FY2025 – – Revuforj® (revumenib) net revenue of $44.2 million in 4Q25, a 38% increase vs 3Q25, and $124.8 million in FY2025 – – Niktimvo™ ...

Sidney must face the horrors of the past when a new Ghostface killer targets her daughter.

Click to share on Facebook (Opens in new window) Facebook Click to share on X (Opens in new window) X ...